Neurological disorders

Supernus Announces Second Quarter 2021 Financial Results

Retrieved on: 
Wednesday, August 4, 2021
Neurological disorders, Psychiatry, Branches of biology, Childhood psychiatric disorders, Communication, Forward-looking statement, Attention deficit hyperactivity disorder, Dystonia, Migraine, Epilepsy

Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases.

Key Points: 
  • Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases.
  • Our diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, ADHD, hypomobility in Parkinsons disease, cervical dystonia and chronic sialorrhea.
  • This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
  • These statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements.

Anavex Life Sciences to Participate in the BTIG Virtual Biotechnology Conference 2021

Retrieved on: 
Wednesday, August 4, 2021
Branches of biology, Neurological disorders, Neuroscience, Developmental neuroscience, Neurodevelopmental disorder, Rett syndrome, Parkinson

Webcast for the conference will be available in the Investors section under "Events" of the Anavex corporate website at www.anavex.com .

Key Points: 
  • Webcast for the conference will be available in the Investors section under "Events" of the Anavex corporate website at www.anavex.com .
  • To listen to the live event, please contact a BTIG representative with interest.
  • About Anavex Life Sciences Corp.
    Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimers disease, Parkinsons disease, Rett syndrome and other central nervous system (CNS) diseases, pain, and various types of cancer.
  • All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

Vestibular Disorders Association Announces Docuseries Life Rebalanced Chronicles: Shares Stories of Invisible Chronic Illness

Retrieved on: 
Wednesday, August 4, 2021
Neurological disorders, Balance disorder

Their message of hope is for everyone who struggles with invisible chronic illness or are navigating life's challenges.

Key Points: 
  • Their message of hope is for everyone who struggles with invisible chronic illness or are navigating life's challenges.
  • The six-episode docuseries airs weekly starting August 10, in conjunction with Balance Awareness Week (Sept. 19-25, 2021).
  • The series is a collaboration between the Vestibular Disorder Association (VeDA) and Kimberly Warner, filmmaker and founder of Unfixed Media .
  • The docuseries features nine vestibular patients who are learning to live with vestibular disorders.

Zogenix to Participate in the BofA Securities SMID Cap 2H21 Ideas Conference

Retrieved on: 
Tuesday, August 3, 2021
Health, Clinical medicine, Neurological disorders, Epilepsy, Rare diseases, CDKL5 deficiency disorder, Syndromes, Dravet syndrome, Lennox–Gastaut syndrome, CDKL5, Fenfluramine, Epilepsy syndromes

Zogenix is a global biopharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their families living with rare diseases.

Key Points: 
  • Zogenix is a global biopharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their families living with rare diseases.
  • The companys first rare disease therapy, FINTEPLA (fenfluramine) oral solution, has been approved by the U.S. FDA and the European Medicines Agency and is in development in Japan for the treatment of seizures associated with Dravet syndrome, a rare, severe lifelong epilepsy.
  • The company has two additional late-stage development programs: one in a rare epilepsy called Lennox-Gastaut syndrome and one in a mitochondrial disease called TK2 deficiency.
  • Zogenix also plans to initiate a study of FINTEPLA in a genetic epilepsy called CDKL5 Deficiency Disorder (CDD) and is collaborating with Tevard Biosciences to identify and develop potential next-generation gene therapies for Dravet syndrome and other genetic epilepsies.

SadBaby is Opening New Doorways for Providing Financial Aid to SMA Patients

Retrieved on: 
Thursday, July 29, 2021
Neurological disorders, Neurodegenerative disorders, Motor neuron diseases, Neurogenetic disorders, Neuromuscular Disorders, Spinal muscular atrophy, SMA

ANTALYA, Turkey, July 29, 2021 /PRNewswire/ --The SadBaby project was recently launched to help SMA (Spinal Muscular Atrophy) patients overcome financial constraints in getting proper medical treatment.

Key Points: 
  • ANTALYA, Turkey, July 29, 2021 /PRNewswire/ --The SadBaby project was recently launched to help SMA (Spinal Muscular Atrophy) patients overcome financial constraints in getting proper medical treatment.
  • The SadBaby Team aims to improve every patient's quality of life and gather sufficient funds to support the affected children and their families.
  • Working together with SMA Association in Antalya, SadBaby has already raised significant donations for babies affected with SMA and is soon organising a concert to further their funding strategy.
  • SadBaby is also planning to create an NFT marketplace where families would be able to sell NFT products and obtain financial help by this year's end.

SadBaby is Opening New Doorways for Providing Financial Aid to SMA Patients

Retrieved on: 
Thursday, July 29, 2021
Neurological disorders, Neurodegenerative disorders, Motor neuron diseases, Neurogenetic disorders, Neuromuscular Disorders, Spinal muscular atrophy, SMA

ANTALYA, Turkey, July 29, 2021 /PRNewswire/ --The SadBaby project was recently launched to help SMA (Spinal Muscular Atrophy) patients overcome financial constraints in getting proper medical treatment.

Key Points: 
  • ANTALYA, Turkey, July 29, 2021 /PRNewswire/ --The SadBaby project was recently launched to help SMA (Spinal Muscular Atrophy) patients overcome financial constraints in getting proper medical treatment.
  • The SadBaby Team aims to improve every patient's quality of life and gather sufficient funds to support the affected children and their families.
  • Working together with SMA Association in Antalya, SadBaby has already raised significant donations for babies affected with SMA and is soon organising a concert to further their funding strategy.
  • SadBaby is also planning to create an NFT marketplace where families would be able to sell NFT products and obtain financial help by this year's end.

US FDA grants VICO Therapeutics Orphan-Drug Designation for VO659, an Investigational Therapy for Huntington Disease

Retrieved on: 
Thursday, July 29, 2021
Neurological disorders, Autosomal dominant disorders, Branches of biology, Clinical medicine, Rare diseases, Trinucleotide repeat disorders, Spinocerebellar ataxia, Ataxia, Huntington's disease, SCA, Dementia

This news comes only one month after VICO announced that VO659 had received orphan-drug designation for the treatment of spinocerebellar ataxia (SCA).

Key Points: 
  • This news comes only one month after VICO announced that VO659 had received orphan-drug designation for the treatment of spinocerebellar ataxia (SCA).
  • This new designation completes the quartet of orphan designations for VO659 in HD and SCA in both the US and EU.
  • Patients affected by Huntington's disease experience motor disturbances, personality changes and dementia, leading to increasing disability, loss of independence and reduced survival.
  • VICO's antisense oligonucleotide platform (AON) is focusing on different forms of spinocerebellar ataxia (SCA) and Huntington Disease (HD).

US FDA grants VICO Therapeutics Orphan-Drug Designation for VO659, an Investigational Therapy for Huntington Disease

Retrieved on: 
Thursday, July 29, 2021
Neurological disorders, Autosomal dominant disorders, Branches of biology, Clinical medicine, Rare diseases, Trinucleotide repeat disorders, Spinocerebellar ataxia, Ataxia, Huntington's disease, SCA, Dementia

This news comes only one month after VICO announced that VO659 had received orphan-drug designation for the treatment of spinocerebellar ataxia (SCA).

Key Points: 
  • This news comes only one month after VICO announced that VO659 had received orphan-drug designation for the treatment of spinocerebellar ataxia (SCA).
  • This new designation completes the quartet of orphan designations for VO659 in HD and SCA in both the US and EU.
  • Patients affected by Huntington's disease experience motor disturbances, personality changes and dementia, leading to increasing disability, loss of independence and reduced survival.
  • VICO's antisense oligonucleotide platform (AON) is focusing on different forms of spinocerebellar ataxia (SCA) and Huntington Disease (HD).

Data for Genentech’s Evrysdi (risdiplam) Published in New England Journal of Medicine Shows Significant Improvement in Survival and Motor Milestones in Babies With Type 1 Spinal Muscular Atrophy (SMA)

Retrieved on: 
Wednesday, July 28, 2021
Research, Baby, Maternity, Clinical trials, Other Health, Biotechnology, General Health, Pharmaceutical, Consumer, Health, Science, Neurological disorders, Branches of biology, Neurodegenerative disorders, Motor neuron diseases, Neurogenetic disorders, Neuromuscular Disorders, SMA, Muscle atrophy, Spinal muscular atrophies, Evrysdi® (risdiplam), SMA, Genentech in Neuroscience, Genentech, EVRYSDI® (RISDIPLAM), SMA, GENENTECH IN NEUROSCIENCE, GENENTECH

Infants were classified as HINE-2 responders if more motor milestones showed improvement than worsened.

Key Points: 
  • Infants were classified as HINE-2 responders if more motor milestones showed improvement than worsened.
  • We will continue to work closely with governments and the SMA community to bring Evrysdi to as many people as possible.
  • Evrysdi is a prescription medicine used to treat spinal muscular atrophy (SMA) in adults and children 2 months of age and older.
  • If Evrysdi gets in ones eyes, rinse ones eyes with water
    The most common side effects of Evrysdi include:

Asceneuron CEO Dirk Beher to Speak at Alzheimer's Association International Conference

Retrieved on: 
Wednesday, July 28, 2021
Branches of biology, Biology, Psychiatric diagnosis, Cognitive disorders, Learning disabilities, Aging-associated diseases, Protein O-GlcNAcase, Neurological disorders, O-GlcNAc, Alzheimer's disease, Parkinson's disease, Dementia

Dr Dirk Beher will discuss the topic "O-GlcNAcase Inhibitors as Therapies for Tauopathies" and will provide an update on the current status of Asceneuron'sO-GlcNAcase inhibitor research and clinical pipeline.

Key Points: 
  • Dr Dirk Beher will discuss the topic "O-GlcNAcase Inhibitors as Therapies for Tauopathies" and will provide an update on the current status of Asceneuron'sO-GlcNAcase inhibitor research and clinical pipeline.
  • The Alzheimer's Association International Conference is the largest and most influential international meeting dedicated to advancing dementia science.
  • Asceneuron is a clinical stage biotech company focused on the development of orally bioavailable therapeutics for debilitating neurodegenerative disorders with high unmet medical need.
  • Asceneuron has two clinical stage small molecule O-GlcNAcase inhibitors in development for the treatment of proteinopathies including Parkinson's Disease, Alzheimer's disease and related disorders.